Waters Corp partners with IMU Bioscience for AI immunology platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2026
0mins
Waters Corp. shares rose 5.02% as the stock reached a 5-day high.
The increase is attributed to the announcement of a strategic partnership with IMU Bioscience, aimed at accelerating the development of an AI-powered immunology platform. This collaboration will leverage Waters' advanced flow cytometry technologies and IMU's HD analysis capabilities, significantly enhancing immune data analysis and potentially leading to novel biomarker discoveries.
This partnership positions Waters Corp. at the forefront of immunology research, promising to improve clinical applications and disease diagnosis through innovative technologies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WAT
Wall Street analysts forecast WAT stock price to rise
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 378.890
Low
350.00
Averages
414.08
High
480.00
Current: 378.890
Low
350.00
Averages
414.08
High
480.00
About WAT
Waters Corporation is a global life sciences and diagnostics company. The Company offers analytical instruments, separations technologies, and software, serving life, materials, food, and environmental sciences. Its segments include Waters and TA. The Company primarily designs, manufactures, sells and services high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. The Company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA Instruments (TA) product line. The Company is also a developer and supplier of advanced software-based products that interface with the Company’s instruments, as well as other manufacturers’ instruments.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Waters Corporation to Hold Q2 2026 Earnings Call on August 4
- Earnings Call Announcement: Waters Corporation will hold its Q2 2026 financial results conference call on August 4, 2026, at 8:00 a.m. Eastern Time, aimed at providing investors and analysts with the latest financial data and company strategy.
- Live Webcast Availability: The presentation will be available via live webcast on Waters' Investor Relations website, ensuring that global investors can access real-time financial information, thereby enhancing transparency and communication efficiency.
- Replay Service: A replay of the webcast will be available until at least September 1, 2026, at midnight Eastern Time, allowing investors who cannot attend live to review the meeting content, further strengthening investor relations management.
- Company Background: Waters Corporation is a global leader in life sciences and diagnostics, dedicated to accelerating the application of science through analytical technologies and informatics, showcasing its significant position in the industry by driving the release of high-quality medicines and ensuring food safety.
See More
Waters Corporation to Hold Q2 2026 Financial Results Conference Call on August 4
- Conference Call Announcement: Waters Corporation will hold its Q2 2026 financial results conference call on August 4, 2026, at 8:00 a.m. Eastern Time, aimed at providing investors and analysts with the latest financial performance and future outlook.
- Live Webcast Availability: The conference will be available via live webcast on Waters' Investor Relations website, ensuring global investors can access real-time financial information, thereby enhancing transparency and investor confidence.
- Replay Service: A replay of the webcast will be available until at least September 1, 2026, at midnight Eastern Time, allowing investors who cannot attend live to review the meeting content, further improving information accessibility.
- Company Background: Waters Corporation is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of science through analytical technologies and informatics, with approximately 16,000 employees focused on the release of high-quality medicines and early disease detection.
See More
Waters Corporation Schedules Q2 2026 Earnings Conference Call
- Earnings Call Announcement: Waters Corporation will hold its Q2 2026 financial results conference call on August 4, 2026, at 8:00 a.m. Eastern Time, aimed at providing investors with insights into the company's financial performance and future outlook.
- Live Webcast Availability: The presentation will be available via a live webcast on Waters' Investor Relations website, ensuring that global investors can access real-time updates on the company's latest developments, thereby enhancing transparency and investor confidence.
- Replay Service: A replay of the webcast will be available until at least September 1, 2026, at midnight Eastern Time, allowing investors who cannot attend the live event to review the information, further improving accessibility to critical updates.
- Company Background: Waters Corporation is a global leader in life sciences and diagnostics, dedicated to advancing scientific progress through analytical technologies and informatics, with approximately 16,000 employees focused on developing high-quality medicines and early disease detection.
See More
Waters and IMU Bioscience Form Strategic Partnership
- Strategic Partnership Launched: Waters Corp. and IMU Bioscience announced a strategic partnership aimed at accelerating the development of IMU's next-generation AI-powered High Definition immunology platform, leveraging both companies' strengths in flow cytometry and single-cell technologies to enhance real-time immune data analysis.
- Technological Integration Benefits: This collaboration combines Waters' advanced flow cytometers and reagents with IMU's HD analysis and AI machine learning analytics, enabling the extraction of over 100 million data points from a single blood sample, significantly improving the reproducibility and depth of immune system characterization.
- Data Set Development: IMU is building the world's largest immune dataset, establishing a universal standard for immune profiling through unparalleled access to patient samples and population-wide clinical data, thereby laying the groundwork for novel biomarker discovery.
- Clinical Application Prospects: The companies plan to pursue additional studies in translational research to enhance clinical applications in flow cytometry, utilizing newly discovered biomarkers to improve disease diagnosis and treatment outcomes, which holds significant market potential and strategic importance.
See More
Waters Launches Innovative Battery Safety Testing Instrument
- Battery Safety Testing Revolution: Waters Corporation's Coin Cell DSC enables direct testing of fully assembled coin cells, eliminating time-consuming preparation steps, thereby accelerating testing speed and providing more detailed safety and performance insights.
- Multidimensional Data Capture: This instrument is the only DSC that simultaneously captures thermal, evolved gas, and electrochemical performance data, helping researchers identify thermal runaway and battery failures earlier, enhancing safety in battery development.
- Significant Reduction in Preparation Time: The new capsule design reduces sample preparation time by over 90%, preserving sample integrity while significantly accelerating data generation and optimizing experimental workflows.
- Broad Application Prospects: With a temperature range of -80°C to 600°C, the Coin Cell DSC enables comprehensive analysis of low- and high-temperature behavior, advancing early-stage battery safety research and reducing development risks.
See More
Waters Launches Innovative BioResolve and GTxResolve Columns for Biopharmaceuticals
- Product Launch: Waters Corporation has introduced the BioResolve™ Peptide and GTxResolve™ Lipid Columns, specifically designed to address the challenge of separating structurally similar impurities in GLP-1 peptides, insulin, and lipid nanoparticles, thereby enhancing the safety and efficacy of drug development.
- Market Demand Response: The new columns significantly improve separation efficiency and speed, helping pharmaceutical companies reduce time to market, enhance regulatory confidence, and lower patient safety risks associated with impurities.
- Technical Advantages: The BioResolve and GTxResolve Columns utilize specially designed surface chemistries and superficially porous particles to ensure consistent performance across U(H)PLC and HPLC systems, suitable for all stages from early research to manufacturing.
- Positive Customer Feedback: Researchers from Alembic Pharmaceuticals and Acuitas Therapeutics have expressed high satisfaction with the new products' separation performance, stating that they can meet current and future regulatory requirements while facilitating rapid analysis of complex peptides and lipids.
See More
Waters Corporation to Hold Q2 2026 Earnings Call on August 4
- Earnings Call Announcement: Waters Corporation will hold its Q2 2026 financial results conference call on August 4, 2026, at 8:00 a.m. Eastern Time, aimed at providing investors and analysts with the latest financial data and company strategy.
- Live Webcast Availability: The presentation will be available via live webcast on Waters' Investor Relations website, ensuring that global investors can access real-time financial information, thereby enhancing transparency and communication efficiency.
- Replay Service: A replay of the webcast will be available until at least September 1, 2026, at midnight Eastern Time, allowing investors who cannot attend live to review the meeting content, further strengthening investor relations management.
- Company Background: Waters Corporation is a global leader in life sciences and diagnostics, dedicated to accelerating the application of science through analytical technologies and informatics, showcasing its significant position in the industry by driving the release of high-quality medicines and ensuring food safety.
See More
Waters Corporation to Hold Q2 2026 Financial Results Conference Call on August 4
- Conference Call Announcement: Waters Corporation will hold its Q2 2026 financial results conference call on August 4, 2026, at 8:00 a.m. Eastern Time, aimed at providing investors and analysts with the latest financial performance and future outlook.
- Live Webcast Availability: The conference will be available via live webcast on Waters' Investor Relations website, ensuring global investors can access real-time financial information, thereby enhancing transparency and investor confidence.
- Replay Service: A replay of the webcast will be available until at least September 1, 2026, at midnight Eastern Time, allowing investors who cannot attend live to review the meeting content, further improving information accessibility.
- Company Background: Waters Corporation is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of science through analytical technologies and informatics, with approximately 16,000 employees focused on the release of high-quality medicines and early disease detection.
See More
Waters Corporation Schedules Q2 2026 Earnings Conference Call
- Earnings Call Announcement: Waters Corporation will hold its Q2 2026 financial results conference call on August 4, 2026, at 8:00 a.m. Eastern Time, aimed at providing investors with insights into the company's financial performance and future outlook.
- Live Webcast Availability: The presentation will be available via a live webcast on Waters' Investor Relations website, ensuring that global investors can access real-time updates on the company's latest developments, thereby enhancing transparency and investor confidence.
- Replay Service: A replay of the webcast will be available until at least September 1, 2026, at midnight Eastern Time, allowing investors who cannot attend the live event to review the information, further improving accessibility to critical updates.
- Company Background: Waters Corporation is a global leader in life sciences and diagnostics, dedicated to advancing scientific progress through analytical technologies and informatics, with approximately 16,000 employees focused on developing high-quality medicines and early disease detection.
See More
Waters and IMU Bioscience Form Strategic Partnership
- Strategic Partnership Launched: Waters Corp. and IMU Bioscience announced a strategic partnership aimed at accelerating the development of IMU's next-generation AI-powered High Definition immunology platform, leveraging both companies' strengths in flow cytometry and single-cell technologies to enhance real-time immune data analysis.
- Technological Integration Benefits: This collaboration combines Waters' advanced flow cytometers and reagents with IMU's HD analysis and AI machine learning analytics, enabling the extraction of over 100 million data points from a single blood sample, significantly improving the reproducibility and depth of immune system characterization.
- Data Set Development: IMU is building the world's largest immune dataset, establishing a universal standard for immune profiling through unparalleled access to patient samples and population-wide clinical data, thereby laying the groundwork for novel biomarker discovery.
- Clinical Application Prospects: The companies plan to pursue additional studies in translational research to enhance clinical applications in flow cytometry, utilizing newly discovered biomarkers to improve disease diagnosis and treatment outcomes, which holds significant market potential and strategic importance.
See More
Waters Launches Innovative Battery Safety Testing Instrument
- Battery Safety Testing Revolution: Waters Corporation's Coin Cell DSC enables direct testing of fully assembled coin cells, eliminating time-consuming preparation steps, thereby accelerating testing speed and providing more detailed safety and performance insights.
- Multidimensional Data Capture: This instrument is the only DSC that simultaneously captures thermal, evolved gas, and electrochemical performance data, helping researchers identify thermal runaway and battery failures earlier, enhancing safety in battery development.
- Significant Reduction in Preparation Time: The new capsule design reduces sample preparation time by over 90%, preserving sample integrity while significantly accelerating data generation and optimizing experimental workflows.
- Broad Application Prospects: With a temperature range of -80°C to 600°C, the Coin Cell DSC enables comprehensive analysis of low- and high-temperature behavior, advancing early-stage battery safety research and reducing development risks.
See More
Waters Launches Innovative BioResolve and GTxResolve Columns for Biopharmaceuticals
- Product Launch: Waters Corporation has introduced the BioResolve™ Peptide and GTxResolve™ Lipid Columns, specifically designed to address the challenge of separating structurally similar impurities in GLP-1 peptides, insulin, and lipid nanoparticles, thereby enhancing the safety and efficacy of drug development.
- Market Demand Response: The new columns significantly improve separation efficiency and speed, helping pharmaceutical companies reduce time to market, enhance regulatory confidence, and lower patient safety risks associated with impurities.
- Technical Advantages: The BioResolve and GTxResolve Columns utilize specially designed surface chemistries and superficially porous particles to ensure consistent performance across U(H)PLC and HPLC systems, suitable for all stages from early research to manufacturing.
- Positive Customer Feedback: Researchers from Alembic Pharmaceuticals and Acuitas Therapeutics have expressed high satisfaction with the new products' separation performance, stating that they can meet current and future regulatory requirements while facilitating rapid analysis of complex peptides and lipids.
See More
